Get startedLog in
    Picture of Candel Therapeutics logo

    CADL — Candel Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareMid CapNeutral
    All News

    Brief: Candel Therapeutics Receives FDA Fast Track Designation For Can-2409 In Non-Small Cell Lung Cancer

    Picture of Candel Therapeutics logoCandel Therapeutics
    17/04/2023 13:02
    April 17 (Reuters) - Candel Therapeutics Inc  CADL.O :
    * CANDEL THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION
FOR
CAN-2409 IN NON-SMALL CELL LUNG CANCER
    * CANDEL THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION
FOR
CAN-2409 IN NON-SMALL CELL LUNG CANCER
    * CANDEL THERAPEUTICS INC - EXPECTS TO PRESENT UPDATED
CLINICAL
DATA FROM ITS PHASE 2 CLINICAL TRIAL IN Q3 OF 2023

Source text for Eikon:  ID:nGNX5LX4nS 
Further company coverage:  CADL.O

    Recent news on Candel Therapeutics

    See all news